Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02013778 | Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC | terminated | Phase 1 / Phase 2 | 8 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 20, 2020 | clinicaltrials |
| NCT00353457 | Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma | terminated | Phase 2 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Apr 9, 2020 | clinicaltrials |
| NCT01333124 | Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma | terminated | Phase 2 | 23 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2020 | clinicaltrials |
| NCT02141295 | A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer(McCAVE) | terminated | Phase 2 | 197 | Hoffmann-La RocheINDUSTRY | 7 | Mar 25, 2020 | clinicaltrials |
| NCT00539617 | Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 7 | University of California, San FranciscoOTHER | 1 | Mar 23, 2020 | clinicaltrials |
| NCT01504477 | Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer | terminated | Phase 1 / Phase 2 | 6 | Georgetown UniversityOTHER | 1 | Mar 16, 2020 | clinicaltrials |
| NCT01057017 | First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras | terminated | Phase 2 | 5 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01669720 | Adjuvant Aflibercept for Metastatic Colorectal Cancer(C261) | terminated | Phase 2 | 10 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01671488 | A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer(276) | terminated | Phase 1 / Phase 2 | 11 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT00955240 | Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer | terminated | Phase 2 | 16 | UNICANCEROTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02425683 | Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX | terminated | Phase 2 | 24 | US Oncology ResearchINDUSTRY | 1 | Feb 10, 2020 | clinicaltrials |
| NCT02743975 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma(PENGUIN) | terminated | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02726399 | Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer | terminated | Phase 2 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT01624090 | Mithramycin for Lung, Esophagus, and Other Chest Cancers | terminated | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2019 | clinicaltrials |
| NCT01532804 | 2nd-line Treatment of Metastatic Colorectal Cancer(BEVATOMOX) | terminated | Phase 2 | 83 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Dec 26, 2019 | clinicaltrials |
| NCT00580073 | Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum | terminated | Phase 2 | 6 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01902823 | Effect of Cancer Nurse Navigators on Patient Outcomes | terminated | Phase 2 / Phase 3 | 16 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01240304 | A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas | terminated | Phase 2 | 10 | University of ArkansasOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma(LAPC-BC-819) | terminated | Phase 2 | 12 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Nov 1, 2019 | clinicaltrials |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2019 | clinicaltrials |
| NCT02318901 | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer(PembroMab) | terminated | Phase 1 / Phase 2 | 16 | Western Regional Medical CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT02352831 | Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 16 | Washington University School of MedicineOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT02570711 | Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer | terminated | Phase 2 | 3 | Acerta Pharma BVINDUSTRY | 1 | Aug 28, 2019 | clinicaltrials |
| NCT00397878 | AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2019 | clinicaltrials |
| NCT00478140 | Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2019 | clinicaltrials |
| NCT03204201 | Validation of ICG to Identify the Urethra During Rectal Surgery | terminated | Phase 1 / Phase 2 | 5 | Oxford University Hospitals NHS TrustOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03204994 | Fluorescence Targeted Pelvic Lymph Node Mapping | terminated | Phase 1 / Phase 2 | 1 | Oxford University Hospitals NHS TrustOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | terminated | Phase 2 | 3 | Effector TherapeuticsINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02955771 | Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma | terminated | Phase 2 | 7 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 17, 2019 | clinicaltrials |
| NCT02124369 | Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)(PRICKLE) | terminated | Phase 2 | 9 | CCTU- Cancer ThemeOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT01313416 | Gemcitabine and CT-011 for Resected Pancreatic Cancer | terminated | Phase 2 | 2 | Augusta UniversityOTHER | 1 | Jul 10, 2019 | clinicaltrials |
| NCT02736578 | Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery | terminated | Phase 2 | 8 | Eben RosenthalOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT03431311 | T Cell Receptor Based Therapy of Metastatic Colorectal Cancer(TCR-CRC-001) | terminated | Phase 1 / Phase 2 | 1 | Oslo University HospitalOTHER | 1 | Jun 13, 2019 | clinicaltrials |
| NCT03082833 | Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy | terminated | Phase 2 | 1 | Samsung Medical CenterOTHER | 1 | May 20, 2019 | clinicaltrials |
| NCT01248299 | Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.(E-DIS) | terminated | Phase 2 | 105 | Centre Oscar LambretOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT03645876 | SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer | terminated | Phase 2 | 12 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT03070574 | Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome(MesaCAPP) | terminated | Phase 2 | 8 | Christoph GascheOTHER | 6 | Apr 18, 2019 | clinicaltrials |
| NCT01479465 | Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma | terminated | Phase 2 | 266 | Gilead SciencesINDUSTRY | 7 | Apr 17, 2019 | clinicaltrials |
| NCT03150628 | Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stomach CAncer: a Feasibility Study(CISCA) | terminated | Phase 2 | 3 | Richard van HillegersbergOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT01365130 | Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen | terminated | Phase 2 | 15 | howard safranOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT03122548 | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers | terminated | Phase 2 | 5 | Aduro Biotech, Inc.INDUSTRY | 1 | Apr 4, 2019 | clinicaltrials |
| NCT02950025 | Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies | terminated | Phase 2 | 5 | Washington University School of MedicineOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT02568046 | Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients | terminated | Phase 1 / Phase 2 | 10 | Symphogen A/SINDUSTRY | 2 | Mar 26, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Apr 20, 2020source: clinicaltrials